Breakthrough Against “The Deadliest Virus”: Japanese Researchers to Launch Human Nipah Vaccine Trials

February 5, 2026

TOKYO/BRUSSELS — A research team at the University of Tokyo announced Wednesday that it will begin Phase 1 human clinical trials for a pioneering Nipah virus vaccine this April. The trials, set to take place in Belgium, represent a critical milestone in the global race to defend against a pathogen the World Health Organization (WHO) identifies as a top priority for research due to its “pandemic potential” and a staggering fatality rate that can reach 75%.

The announcement comes at a time of heightened vigilance. Just last month, health authorities in West Bengal, India, confirmed two new cases of the virus, underscoring the persistent threat of zoonotic “spillover” events in South Asia. Despite decades of sporadic outbreaks, there is currently no licensed vaccine or specific treatment available for the Nipah virus (NiV).

A “Trojan Horse” Strategy: The Measles Connection

The vaccine candidate, developed by the University of Tokyo’s Institute of Medical Science, utilizes a sophisticated “viral vector” approach. Researchers have modified the existing, highly successful measles vaccine by inserting a specific segment of the Nipah virus’s genetic code.

This strategy essentially uses the measles virus as a delivery vehicle—a “Trojan Horse”—to introduce Nipah antigens to the human body. Once administered, the body produces proteins that mimic the Nipah virus, “training” the immune system to recognize and fight the real pathogen without the recipient ever being exposed to the actual deadly virus.

“The modified measles virus platform is a proven workhorse in global immunization,” noted the research team in a statement reported by Nikkei Asia. “By leveraging this established technology, we aim to trigger a robust immune response that can prevent the onset of severe symptoms.”

Clinical Trial Roadmap

The upcoming Phase 1 trial in Belgium will focus primarily on safety and dosage, involving 60 healthy volunteers. This follows successful animal studies in hamsters and non-human primates, where the vaccine demonstrated both safety and high efficacy in preventing lethal outcomes.

If the Belgian trials prove successful, the research is slated to move to its most critical phase in the second half of 2027: expanded trials in Bangladesh. Unlike Belgium, Bangladesh is an endemic region where the virus often jumps from fruit bats to humans via contaminated date palm sap, providing the necessary environment to test the vaccine’s real-world effectiveness.

The Global Landscape: Oxford and Beyond

The Japanese team is not alone in this high-stakes endeavor. They are joined by researchers from Oxford University, who launched the world’s first Phase 2 clinical trial of their own Nipah vaccine candidate (ChAdOx1 NipahB) in Bangladesh this past December.

“Starting trials in countries affected by regular outbreaks is a critical step,” said Professor Brian Angus, Chief Investigator of the Oxford trial. “It is about ensuring equitable access to protection for the populations most at risk.”

Public Health Implications

Nipah is a zoonotic disease, primarily transmitted from Pteropus fruit bats to humans, either through direct contact or contaminated food. It can also spread from animals like pigs and, significantly, through human-to-human contact.

For the general public, the development of a vaccine is less about an immediate threat of a global lockdown and more about “ring vaccination” strategies. This involves vaccinating the “ring” of people around an infected individual to stop an outbreak in its tracks—a strategy that was famously used to eradicate smallpox.

Limitations and Challenges

While the news is promising, experts urge caution. Developing a vaccine for a rare but deadly virus presents unique hurdles:

• Low Case Numbers: Because Nipah outbreaks are sporadic and involve relatively few people compared to flu or COVID-19, proving that a vaccine actually prevents infection in the field takes significantly longer.

• Bio-Safety Requirements: Working with the live Nipah virus requires Level 4 Biosafety (BSL-4) labs—the highest security level—which limits the number of facilities that can conduct research.

• Viral Diversity: There are different strains of Nipah (the Malaysia strain vs. the Bangladesh/India strain). A vaccine must ideally be effective against both.

What This Means for You

For those living outside of South and Southeast Asia, the risk remains exceptionally low. However, for healthcare workers and residents in endemic regions, a successful vaccine could be the difference between a contained incident and a localized tragedy.

Public health officials emphasize that until a vaccine is available, prevention remains the best defense:

1. Avoid raw date palm sap in areas where bats are present.

2. Wash and peel fruits thoroughly.

3. Maintain strict hygiene and use personal protective equipment (PPE) when caring for those with respiratory or neurological symptoms in high-risk areas.

As the University of Tokyo moves into human trials this April, the world watches closely, hoping to finally close the door on one of nature’s most lethal pathogens.

References

• https://tennews.in/japanese-researchers-to-begin-human-trial-for-nipah-vaccine-in-april/

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.